Format

Send to

Choose Destination
Biochim Biophys Acta. 2015 Jun;1852(6):1178-85. doi: 10.1016/j.bbadis.2014.11.004. Epub 2014 Nov 8.

Resveratrol and cancer: Challenges for clinical translation.

Author information

1
Department of Dermatology, University of Wisconsin, Madison, WI 53706, USA.
2
Department of Dermatology, University of Wisconsin, Madison, WI 53706, USA. Electronic address: nahmad@wisc.edu.

Abstract

Significant work has been done towards identifying the health-beneficial effects of the grape antioxidant resveratrol in a variety of bioassay- and disease- models, with much research being focused on its possible application to cancer management. Despite the large number of preclinical studies dealing with different aspects of the biological effects of resveratrol, its translation to clinics is far from reality due to a variety of challenges. In this review, we discuss the issues and questions associated with resveratrol becoming an effective in vivo anticancer drug, from basic metabolic issues to the problems faced by incomplete understanding of the mechanism(s) of action in the body. We also explore efforts taken by researchers, both public and private, to contend with some of these issues. By examining the published data and previous clinical trials, we have attempted to identify the problems and issues that hinder the clinical translation of resveratrol for cancer management. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

KEYWORDS:

Cancer; Clinical trial; Resveratrol

PMID:
25446990
PMCID:
PMC4380791
DOI:
10.1016/j.bbadis.2014.11.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center